Skip to main content
OpenTrials
Completed

NCT Number: NCT03895385

A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects

The purpose of the study is to evaluate whether administration of bimekizumab has an effect on the expected production of antibody titers to the influenza vaccine.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Volunteers

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Up0034 001

San Antonio, Texas, 78209, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is male or female aged ≥18 years and ≤55 years at the Screening Visit
  • Subject must have a blood test with at least two influenza antibody titers ≤1/10 at the Screening Visit and have not developed any flu-like illness 2 weeks before the start of the study
  • Female subjects of childbearing potential must not be lactating and have a negative serum pregnancy test at the Screening Visit, which is confirmed to be negative by urine testing prior to administration of bimekizumab. Female subjects of childbearing potential must agree to use a highly effective method of birth control during the study and for a period of 20 weeks after their last dose of the investigational medicinal product (IMP)
  • Subject has a body weight of ≥45 kg and body mass index (BMI) between 18 and 32 kg/m2 (inclusive), at the Screening Visit

Exclusion criteria

  • Subject has a known hypersensitivity to any excipients of bimekizumab
  • Subject has a history of hypersensitivity to the influenza vaccine
  • Subject is legally institutionalized or has a mental health condition or related care provision (eg, guardianship) that would impede the subject from providing voluntary informed consent to participate in the study
  • Female subject who is pregnant, or plans to become pregnant during the study, or lactating, or sexually active with childbearing potential who is not using a medically accepted birth control method
  • Male subjects who are planning a partner pregnancy during the study
  • Subjects receiving vaccination of any kind within the 52 weeks prior to the Screening Visit or the influenza vaccination within 2 years prior to the Screening Visit. Live vaccines are not allowed during the study or for 20 weeks after the last dose of investigational medicinal product (IMP)
  • Subject has a current or past history of gastrointestinal ulceration or other gastrointestinal disease, such as inflammatory bowel disease
  • Subject has an active infection
  • Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection or human T-cell lymphotropic virus type-1 (HTLV-1)

Treatment and study plan

Bimekizumab

Drug

Subjects will receive a single dose bimekizumab at a predefined time point during the Treatment Period.

Other names: BKZ, UCB4940

Primary outcomes

  1. Seroconversion response

    Time frame: From Baseline (Day 1 pre-dose) to 4 weeks post-vaccination (Day 43)

    A subject is considered as a seroconversion responder if the following is true: subject has either a pre-vaccination HI titer ≤1/10 and a 4-week post-vaccination HI titer ≥1/40 or a pre-vaccination HI titer >1/10 and a ≥4fold increase in HI titer 4 weeks after vaccination in at least 2 out of 4 serotypes.

  2. Plasma concentration of bimekizumab (BKZ)

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

    Bimekizumab plasma concentrations by scheduled sampling time.

  3. Incidence of Adverse Events (AE) from Baseline to Safety Follow Up

    Time frame: From Baseline to Safety Follow Up (up to Day 140)

    An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.

Secondary outcomes

  1. Influenza antibody geometric mean titers (GMT)

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

    Post-vaccination influenza antibody geometric mean titers.

  2. Area under the BKZ plasma concentration-time curve over the first 14 days AUC(0-14)

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 14)

    The AUC(0-14) is the area under the plasma concentration-time curve from time zero to day 14.

  3. Area under the BKZ plasma concentration-time curve over the first 28 days AUC(0-28)

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 28)

    The AUC(0-28) is the area under the plasma concentration-time curve from time zero to day 28.

  4. Area under the BKZ plasma concentration-time curve from time zero to last quantifiable concentration (AUCt)

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

    The AUCt is the area under the plasma concentration-time curve from time zero to last quantifiable concentration (AUCt) of BKZ as determined using the linear trapezoidal rule.

  5. Area under the BKZ plasma concentration-time curve from time zero to infinity (AUC)

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

    The area under the plasma concentration-time curve from time zero to infinity (AUC) of BKZ is calculated as AUC=AUCt+Clast/λz, where Clast is the last quantifiable plasma concentration and λz is the apparent terminal elimination rate constant.

  6. Maximum observed BKZ plasma drug concentration (Cmax)

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

    Cmax is the maximum plasma drug concentration of BKZ observed from pharmacokinetic samples taken at predefined time points.

  7. Time of occurrence of the maximum observed BKZ plasma drug concentration (tmax)

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

    Tmax is the time to reach maximum plasma concentration.

  8. Apparent terminal half-life (t1/2)

    Time frame: From Baseline (Day 1 pre-dose) at predefined time points (up to Day 140)

    Apparent terminal half-life, reported in units of days, as determined via simple linear regression (slope=-λz) of natural log (ln) concentration versus time for data points in the terminal phase of the concentration-time curve. t1/2 is calculated as ln2/λz.

Sponsors and collaborators

Lead sponsor

UCB Biopharma S.P.R.L.

Industry

Registry information

Official study title

An Open-Label, Randomized, Parallel-Group, Single-Dose Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy Subjects

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Mar 29, 2019
Registry last updated
Sep 17, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.